Metachromatic leukodystrophy (MLD) is a rare autosomal recessive lysosomal storage disorders disorder caused by deficiency of arylsulfatase A (ARSA), leading to accumulation of sulfatides (galactosylceramide sulfates) in the white matter of the central nervous system and peripheral nerves. This progressive demyelinating disease primarily affects children but can present at any age, causing severe neurological decline and premature death.
| Form |
Age of Onset |
Progression |
Clinical Features |
| Late Infantile |
1-2 years |
Rapid |
Motor regression, gait disturbance, seizures |
| Juvenile |
3-16 years |
Variable |
Cognitive decline, motor symptoms |
| Adult |
>16 years |
Slow |
Psychiatric symptoms, dementia |
- Incidence: 1 in 40,000 - 1 in 160,000 (varies by population)
- Carrier Frequency: ~1 in 40-80 in general population
- Founder Mutations: Common in Amish, Mennonite, Portuguese populations
MLD results from mutations in the ARSA gene located on chromosome 22q13.31:
flowchart TD
A["ARSA Gene Mutation<br/>Chromosome 22q13.31 → BArylsulfatase A Enzyme<br/>Deficiency"]
B --> C["Sulfatide Accumulation<br/>in Myelin"]
C --> D["Oligodendrocyte Dysfunction"]
C --> E["Schwann Cell Dysfunction"]
D --> F["Demyelination<br/>CNS"]
E --> G["Demyelination<br/>PNS"]
F --> H["White Matter Degeneration"]
G --> H
H --> I["Motor Symptoms"]
H --> J["Cognitive Decline"]
I --> K["Progressive Disability"]
J --> K
K --> L["Premature Death"]
style A fill:#f3e5f5,stroke:#333
style F fill:#f66,stroke:#333
style G fill:#f66,stroke:#333
style K fill:#fff9c4,stroke:#333
- Sulfatide Accumulation: ARSA normally degrades sulfatides; deficiency causes toxic buildup
- Oligodendrocyte Death: Sulfatides are toxic to myelin-producing cells
- Myelin Instability: Accumulated sulfatides disrupt myelin lipid organization
- Axonal Degeneration: Secondary to demyelination
- ARSA-Pseudodeficiency: Common variant with reduced but not absent enzyme activity
- No Clinical Symptoms: Usually benign; can complicate diagnosis
- Missense Mutations: Most common; genotype-phenotype correlation variable
- Nonsense Mutations: Often cause severe (infantile) form
- Splice Site Mutations: Can cause frameshift and premature termination
- Large Deletions: Less common, severe phenotype
| Population |
Common Mutation |
Form |
| Amish |
c.526C>T (p.Arg176*) |
Infantile |
| European |
c.459+1G>A (splice site) |
Infantile |
| Portuguese |
c.542T>G (p.Leu181Arg) |
Juvenile |
| Turkish |
c.643C>T (p.Arg215Cys) |
Variable |
- Two Null Alleles: Severe infantile form
- One Null + One Missense: Variable, often juvenile
- Two Missense: Usually adult onset, milder
- Motor Regression: Loss of previously acquired motor skills
- Hypotonia: Progressive muscle weakness
- Ataxia: Gait disturbance, coordination loss
- Seizures: Often generalized tonic-clonic
- Optic Atrophy: Visual impairment
- Peripheral Neuropathy: Reduced reflexes, distal weakness
- Cognitive Decline: Progressive intellectual disability
- Behavioral Changes: Attention deficit, personality changes
- Motor Symptoms: Gait disturbance, spasticity
- Speech Impairment: Dysarthria, eventual loss
- Psychiatric Symptoms: Depression, psychosis, schizophrenia-like
- Cognitive Decline: Progressive dementia
- Motor Symptoms: Often milder than childhood forms
- Peripheral Neuropathy: May be presenting feature
| Marker |
Finding |
| ARSA Enzyme Activity |
Deficient in leukocytes/fibroblasts |
| MRI Brain |
Tiger stripe pattern, diffuse white matter T2 hyperintensity |
| Nerve Conduction |
Demyelinating peripheral neuropathy |
| Urine Sulfatides |
Elevated (elevated sulfatide excretion) |
| Genetic Testing |
ARSA mutation analysis |
- Tiger Stripe Pattern: Radial stripes in periventricular white matter
- Diffuse Demyelination: Confluent T2 hyperintensities
- Posterior Predominance: Often more severe in posterior brain regions
- Cerebellar Atrophy: In later stages
- Sparing of U-Fibers: Relative preservation initially
- Lysosomal Dysfunction: Common with other LSDs and some forms of AD/PD
- Myelin Breakdown: Similar patterns to other leukodystrophies
- Oxidative Stress: Elevated in MLD and neurodegenerative
- Neuroinflammation: Glial activation in demyelinated regions
MLD serves as a model for understanding:
- Lysosomal storage
- Demyelinating disorders
- White matter degeneration
- Gene therapy approaches
| Treatment |
Indication |
Status |
| Hematopoietic Stem Cell Transplant |
Early disease |
Established |
| Enzyme Replacement Therapy |
All forms |
In development |
| Gene Therapy |
Early disease |
FDA approved (Libmeldy) |
| Substrate Reduction Therapy |
All forms |
Investigational |
| Supportive Care |
All stages |
Standard |
- Type: Autologous gene therapy
- Mechanism: Ex vivo ARSA gene addition to hematopoietic stem cell transplantations
- Efficacy: Preserves motor function in early infantile MLD
- Approval: FDA approved (2024), EMA approved (2020)
- AAV gene therapy Vector Gene Therapy: Direct CNS delivery
- Novel ERT: Brain-penetrant enzyme replacement therapy
- Substrate Reduction Therapy: Reduce sulfatide production
- Small Molecule Therapies: Chaperone
- Physical Therapy: Maintain mobility
- Occupational Therapy: Adaptive equipment
- Speech Therapy: Communication support
- Seizure Management: Antiepileptic drugs
- Nutritional Support: Feeding assistance as needed
- ARSA-/- Mouse: Spontaneous sulfatide accumulation
- Transgenic Models: Human ARSA mutations
- Phenotype: Progressive demyelination, motor deficits
- Gene therapy testing
- ERT development
- Biomarker studies
- Natural history studies
- Gene Therapy Outcomes: Long-term follow-up of Libmeldy shows sustained benefit
- Newborn Screening: Implementation increasing early detection
- Biomarker Development: Neurofilament light chain as disease progression marker
- Natural History: Better understanding of genotype-phenotype correlations
- Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
- Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
- Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury
- BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data